Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal

In the field of rare diseases (RDs), the evidence standard is often lower than that required by health technology assessment (HTA) and payer authorities. In this commentary, we propose that appropriate economic evaluation for rare disease treatments should be initially informed by cost-of-illness (C...

Full description

Bibliographic Details
Main Authors: Patrizio Armeni, Marianna Cavazza, Entela Xoxi, Domenica Taruscio, Yllka Kodra
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:International Journal of Environmental Research and Public Health
Subjects:
Online Access:https://www.mdpi.com/1660-4601/18/3/1101